Eli Lilly and Company (NYSE:LLY) recently announced that Australia's Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, making it the country’s first amyloid-targeting treatment available for the ...

The Therapeutic Goods Administration has registered pharmaceutical giant Eli Lilly's drug Kisunla (donanemab) for use by those with early symptomatic Alzheimer's who also have a presence of amyloid ...

INDIANAPOLIS, May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla ...

A drug that's been found to slow the progress of Alzheimer's disease by clearing proteins in the brain has been approved for use in Australia. The Therapeutic Goods Administration (TGA) has approved a ...